Selective cytopheresis devices and related methods thereof
Inventors
Humes, H. David • Buffington, Deborah
Assignees
University of Michigan Ann Arbor • Seastar Medical Inc
Publication Number
US-8251941-B2
Publication Date
2012-08-28
Expiration Date
2028-08-29
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention relates to systems and devices to treat and/or prevent inflammatory conditions within a subject and to related methods. More particularly, the invention relates to systems, devices, and related methods that sequester leukocytes and/or platelets and then inhibit their inflammatory action.
Core Innovation
The present invention provides systems, devices, and methods to treat and/or prevent inflammatory conditions by extracorporeally sequestering one or both of leukocytes and platelets and inhibiting their inflammatory actions. These systems operate by selectively removing activated or primed leukocytes and/or platelets from a subject’s body fluid, and then deactivating them or inhibiting their release of pro-inflammatory substances before returning them to the subject or discarding them.
A major aspect of the invention is the use of a device, such as a selective cytopheresis inhibitory device (SCID), that contains a region (for example, the external surface of hollow fibers) configured to enable leukocyte sequestration. The system provides an agent, preferably a calcium chelating agent such as citrate, which is capable of inhibiting the release of a pro-inflammatory substance from these cells or deactivating them. The invention details various system configurations, including single-device and multiple-device setups, as well as compatibility with established extracorporeal blood processing systems.
The problem addressed is that current therapies for inflammatory conditions like systemic inflammatory response syndrome (SIRS), sepsis, and related disorders remain inadequate, often associated with high mortality, expensive targeted drugs, and serious adverse reactions. The invention seeks to provide an effective treatment by controlling the activity of inflammation-associated cells through sequestration and targeted deactivation, demonstrating efficacy across multiple types of inflammatory diseases and clinical scenarios.
Claims Coverage
There are two main inventive features presented in the independent claims.
Extracorporeal sequestration and treatment of primed or activated leukocytes with a calcium chelator
A method for processing a leukocyte contained within a body fluid that comprises: - Extracorporeally sequestering a primed or activated leukocyte. - Treating the leukocyte with a calcium chelator to inhibit release of a pro-inflammatory substance or to deactivate the leukocyte.
Treatment of a subject at risk of or having an inflammatory condition via extracorporeal leukocyte sequestration and calcium chelator treatment
A method for treating a subject at risk of developing or having an inflammatory condition comprising: - Extracorporeally sequestering a primed or activated leukocyte from the subject. - Treating the leukocyte with a calcium chelator to reduce the risk of developing inflammation associated with the inflammatory condition or to alleviate existing inflammation.
The inventive features are focused on methods for extracorporeal sequestration of leukocytes and their treatment with a calcium chelator to modulate inflammatory responses, either generally or within the context of a subject at risk of or experiencing specific inflammatory conditions.
Stated Advantages
The invention provides unprecedented and surprising success in maximizing subject survival in various models of inflammation.
Systems and devices can reduce the multi-organ effects of inflammatory diseases and conditions such as sepsis and SIRS.
The methods efficiently sequester and deactivate inflammatory cells, thereby ameliorating inflammation-related tissue damage.
Use of citrate as a calcium chelator in combination with the invention improves innate immunologic system function.
Applicable across a wide range of therapeutic, diagnostic, and research scenarios for different inflammatory diseases and procedures.
Documented Applications
Treatment or prevention of systemic inflammatory response syndrome (SIRS), sepsis, cardiopulmonary bypass syndrome, and acute respiratory distress syndrome (ARDS).
Treatment or prevention of inflammatory conditions such as rheumatoid arthritis, systemic lupus erythematosis, inflammatory bowel disease, multiple sclerosis, psoriasis, allograft rejection, asthma, acute and chronic renal failure, cardiorenal syndrome, hepatorenal syndrome, and acute organ failure from ischemic reperfusion injury.
Prevention and treatment of organ injury arising from medical interventions, including organ transplantation, cardiopulmonary bypass, and dialysis.
Support of ex vivo tissue and organ development, including organ harvesting, tissue engineering, ex vivo organ generation, and bio-microelectromechanical system manufacturing.
Treatment of chronic pro-inflammatory states such as end-stage renal disease.
Therapeutic use in trauma cases, cell therapy, and managing immune-mediated organ dysfunction.
Interested in licensing this patent?